ITM | Jotup

ICPO Foundation partners with ITM to fund 100 stipends of its Academy for Theranostics in China, India, Africa, and Latin America

Retrieved on:

Thursday, January 25, 2024

The stipends will be offered in China, India, Africa and Latin America.

Key Points:

The stipends will be offered in China, India, Africa and Latin America.
This led to the official launch of the Academy for Theranostics by the ICPO Foundation in October 2023.
The ICPO Academy for Theranostics addresses this imperative by offering an extensive educational program developed by the ICPO Foundation.
This collaboration with ITM enables us to award 100 stipends to recipients across three continents."

Grow Financial Federal Credit Union Streamlines, Enhances Self-Service Banking Through NCR Atleos Partnership

Retrieved on:

Tuesday, January 23, 2024

Banking, Fintech, Professional Services, Credit union, ATM, Partnership, Environment, ITM, Grow, Ageing, EVP, Growth, Bank

NCR Atleos Corporation (NYSE: NATL) (“Atleos”), a leader in expanding financial access for financial institutions, retailers and consumers, today announced that Grow Financial Federal Credit Union has chosen Atleos ATM as a Service (ATMaaS) to transform its self-service banking channel for members and support ongoing growth.

Key Points:

NCR Atleos Corporation (NYSE: NATL) (“Atleos”), a leader in expanding financial access for financial institutions, retailers and consumers, today announced that Grow Financial Federal Credit Union has chosen Atleos ATM as a Service (ATMaaS) to transform its self-service banking channel for members and support ongoing growth.
Tampa, Fla.-based Grow Financial recognized the need to update its aging ATM infrastructure and wanted to simultaneously grow its ITM footprint to connect with members in new and engaging ways.
The credit union decided to expand its relationship with Atleos, selecting both Atleos ATMaaS and Atleos ITMs.
This commitment drives us to make sure our self-service banking options are reliable, member-centric, and easy to use," emphasized Doug Tilden, EVP and Chief Financial Officer at Grow Financial Federal Credit Union.

The Green Hydrogen Market Opportunities Explode, Igniting Tremendous Growth From $6 Billion in 2023 to $84 Billion by 2029- Arizton

Retrieved on:

Tuesday, January 16, 2024

The feasibility of green hydrogen production is currently contingent on the development of demand and the global market growth, both of which remain relatively limited.

Key Points:

The feasibility of green hydrogen production is currently contingent on the development of demand and the global market growth, both of which remain relatively limited.
The widespread adoption of green hydrogen can stimulate competitive value chains and create new investment opportunities for nations trying to position themselves in this burgeoning industry.
Despite being in its early stages, the global market for green hydrogen holds significant potential in the energy transition scenario.
The green hydrogen market has been gaining significant attention and undergoing dynamic changes.

The Green Hydrogen Market Opportunities Explode, Igniting Tremendous Growth From $6 Billion in 2023 to $84 Billion by 2029- Arizton

Retrieved on:

Tuesday, January 16, 2024

The feasibility of green hydrogen production is currently contingent on the development of demand and the global market growth, both of which remain relatively limited.

Key Points:

The feasibility of green hydrogen production is currently contingent on the development of demand and the global market growth, both of which remain relatively limited.
The widespread adoption of green hydrogen can stimulate competitive value chains and create new investment opportunities for nations trying to position themselves in this burgeoning industry.
Despite being in its early stages, the global market for green hydrogen holds significant potential in the energy transition scenario.
The green hydrogen market has been gaining significant attention and undergoing dynamic changes.

ITM Appoints Dr. Mark Harfensteller as Member of its Executive Board

Retrieved on:

Tuesday, January 16, 2024

Garching / Munich, Germany, January 16, 2024 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced the appointment of Dr. Mark Harfensteller to its Executive Board.

Key Points:

Garching / Munich, Germany, January 16, 2024 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced the appointment of Dr. Mark Harfensteller to its Executive Board.
Since 2016, he has held the position of Chief Operating Officer (COO) and Managing Director of ITM Medical Isotopes GmbH, a subsidiary of ITM SE.
As a Societas Europaea (“SE”) entity, ITM SE is governed by a two-tier board structure consisting of an Executive Board and a Supervisory Board, in which the latter oversees the Executive Board.
Under this framework, the Executive Board is comprised of members of the management team, while the Supervisory Board is generally controlled by shareholders.

U.S. Eagle Federal Credit Union's South Valley Branch Coming Soon

Retrieved on:

Tuesday, January 9, 2024

Summer, ITM

The full-service branch will be the second location to feature the Interactive Teller Machines (ITM) and the first completely bilingual staffed location.

Key Points:

The full-service branch will be the second location to feature the Interactive Teller Machines (ITM) and the first completely bilingual staffed location.
The tenth U.S. Eagle location will also feature a drive-up ATM in addition to the two ITM lanes.
"We are absolutely thrilled about the launch of our new South Valley branch."
This new branch concept was first launched at the Juan Tabo location in 2021, with the most recent build of the new Academy Branch.

ITM Announces Operational Readiness for NOVA Facility, the World’s Largest Lutetium-177 Production Site

Retrieved on:

Thursday, January 4, 2024

Radionuclide, Quality control, Waste management, Cancer, Laboratory, RPT, NOVA, ITM, Patient, Safety, Radiopharmaceutical, Automation, Medical imaging

Lutetium-177

Key Points:

Lutetium-177
Garching / Munich, January 4, 2024 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced the receipt of the Radioactive Material Handling License (RAM License) for the company’s NOVA facility , the world’s largest Lutetium-177 production site.
Having obtained the RAM License together with other regulatory approvals required, ITM has achieved operational readiness.
The fit-out of NOVA has been completed, with all major production, safety and quality control systems installed.
Based on its size and production scale, NOVA could potentially serve up to several hundred thousand patients worldwide per year.

Security Bank of Kansas City Expands Partnership with NCR Atleos to Transform Self-Service Banking

Retrieved on:

Thursday, January 4, 2024

Banking, Fintech, Professional Services, Finance, Ageing, ATM, Security Bank, EVP, ITM, Bank

NCR Atleos Corporation (NYSE: NATL) (“Atleos”), a leader in expanding financial access for financial institutions, retailers and consumers, today announced that Security Bank of Kansas City has selected NCR Atleos ATM as a Service as well as Atleos ITM as a Service to enable simple, convenient self-service banking for customers.

Key Points:

NCR Atleos Corporation (NYSE: NATL) (“Atleos”), a leader in expanding financial access for financial institutions, retailers and consumers, today announced that Security Bank of Kansas City has selected NCR Atleos ATM as a Service as well as Atleos ITM as a Service to enable simple, convenient self-service banking for customers.
Security Bank of Kansas City has been serving businesses and consumers in and around Kansas City for 90 years.
A growing but aging ATM fleet caused the bank to reconsider the deployment model and strategy behind its self-service banking offerings.
Now relying on Atleos for comprehensive ATM and ITM management and deployment as well, we will be able to evolve our self-service strategy with greater efficiency and ease,” said Thomas Davies, EVP/Chief Retail Officer at Security Bank of Kansas City.

ITM to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Retrieved on:

Thursday, December 21, 2023

Radionuclide, Cancer, PST, Quality of life, Conference, Patient, Therapy, CFO, ITM

Garching / Munich, Germany, December 21, 2023 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that CEO, Steffen Schuster and CFO, Dr. Klaus Maleck will participate in the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco.

Key Points:

Garching / Munich, Germany, December 21, 2023 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that CEO, Steffen Schuster and CFO, Dr. Klaus Maleck will participate in the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco.
Steffen Schuster will present a corporate overview on Tuesday, January 9, 2024, at 9:00 am PST.
ITM, a leading radiopharmaceutical biotech company, is dedicated to providing a new generation of radiomolecular precision therapeutics and diagnostics for hard-to-treat tumors.
We aim to meet the needs of cancer patients, clinicians and our partners through excellence in development, production and global supply.

ITM Executes License Agreement to Obtain Worldwide Exclusive License for the Clinical Development and Commercialization of Folate-Based Radiotheranostics

Retrieved on:

Thursday, December 14, 2023

Merck Group, Research group, Ovarian cancer, Cancer, Doctor of Philosophy, ITM, Merck, Patient, PSI

Under the terms of the agreement, the company will supply ITM with its first-in-class folate precursors for radiolabeling, which ITM will use to advance the clinical and potential future commercial development of its folate receptor-targeting radiopharmaceutical pipeline candidates.

Key Points:

Under the terms of the agreement, the company will supply ITM with its first-in-class folate precursors for radiolabeling, which ITM will use to advance the clinical and potential future commercial development of its folate receptor-targeting radiopharmaceutical pipeline candidates.
The worldwide exclusive license has been expanded to all folate-receptor-positive malignant tumors.
ITM’s theranostic pairing, ITM-55D/ITM-52 is designed to address current limitations in both the screening and treatment paradigm.
“Exercising and expanding our licensing agreement with Merck KGaA, Darmstadt, Germany will greatly support our efforts to rapidly progress our folate-receptor targeting candidate toward phase I clinical evaluation,” commented Steffen Schuster, CEO of ITM.